Novartis India
- Market cap
- ₹ 4,530 Cr.
- P/E
- 45.6x
- P/B
- 5.09x
- 52-week range
- 950 – 2,588.8
- ROE
- 12%
- ROCE
- 16%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Novartis India Limited is an India-based pure-play medicines company. The Company is focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are added for continued investment into R&D and manufacturing scale. The Company’s brands hold key positions in therapeutic areas, such as, Voveran, which is the brand for bone and pain; Simulect, Certican, Sandimmun, Neoral, and Myfortic, which is the brand for transplantation immunology; and Tegrital and Exelon, which is the brand for neurosciences. Its pipeline includes AAA614 Solid tumors, AAA617 Pluvicto Oligometastatic prostate cancer, Pluvicto Metastatic hormone sensitive prostate cancer (mHSPC), 225Ac-PSMA-617 Metastatic castration-resistant prostate cancer (mCRPC), and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Novartis India against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)45.6 against a typical 34.3: pricier than most peers (1st = cheapest).147th of 220
- Sales growth+18.2% against a typical +15.6% from a year earlier.88th of 197
- Profit growth+14.3% against a typical +18.9% from a year earlier.93rd of 160
- Share price, 3 months+13.4% against a typical −0.5%.51st of 200
- Size₹ 4,530.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).54th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A / CARE A2+ | Stable | 7 Oct 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 7 Oct 2026 | New rating | CARE A / CARE A2+ | High | CARE | ₹ 1,000 Cr. |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 85 | 81 | 92 | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 |
| Expenses | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 |
| Operating Profit | 17 | 20 | 11 | 24 | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 |
| OPM % | 21% | 23% | 14% | 26% | 21% | 28% | 29% | 31% | 26% | 26% | 23% | 34% |
| Other Income | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Profit before tax | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 |
| Tax % | 27% | 36% | 31% | 24% | 26% | 28% | 14% | 26% | 26% | 46% | 16% | 25% |
| Net Profit | 24 | 27 | 15 | 26 | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 |
| EPS in Rs | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 | 10.31 | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −6%
- 5 Years
- −1%
- 3 Years
- −2%
- TTM
- 5%
- 10 Years
- −7%
- 5 Years
- 35%
- 3 Years
- −3%
- TTM
- −5%
- 10 Years
- 8%
- 5 Years
- 13%
- 3 Years
- 28%
- TTM
- —
- 10 Years
- 8%
- 5 Years
- 11%
- 3 Years
- 12%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Novartis India | ₹ 1,810.40 | ₹ 4,530 Cr. | 45.6x | 5.1x | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Shilpa Joshi
- Chief Financial Officer, Whole-Time Director
- Chandni Maru
- Chief Compliance Officer, Company Secretary
- Falin Ishwarlal Majmudar
- Additional Director (Whole-Time Director)
Prices are delayed and for information only. Nothing on this page is investment advice.